Literature DB >> 7913890

A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.

R Ben-Levy1, H F Paterson, C J Marshall, Y Yarden.   

Abstract

The transforming potential of the Neu/ErbB-2 receptor tyrosine kinase undergoes inactivation by deletion of the non-catalytic C-terminal tail, which contains five autophosphorylation sites. To determine which site is essential for oncogenicity, we tailed the C-terminally-deleted mutant with individual autophosphorylation sites. Complete restoration of the transforming action in vitro and in vivo was conferred by a stretch of 12 amino acids that contained the most C-terminal tyrosine autophosphorylation site (Y1253). Reconstitution of transformation was specific to this amino acid sequence because none of the other autophosphorylation sites, when grafted individually, caused transformation, and replacement of the tyrosine with a phenylalanine residue significantly reduced the oncogenic potential of both the full-length and the tailed proteins. When present alone the most C-terminal sequence enabled coupling to a biochemical pathway that includes Ras, MAP kinase and transactivation of Jun. These results indicate that the multiplicity of autophosphorylation sites on a receptor tyrosine kinase is not essential for transformability, and implicate the MAP kinase pathway in transduction of the oncogenic signal of Neu/ErbB-2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913890      PMCID: PMC395227          DOI: 10.1002/j.1460-2075.1994.tb06632.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  40 in total

1.  Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73.

Authors:  T Smeal; B Binetruy; D Mercola; A Grover-Bardwick; G Heidecker; U R Rapp; M Karin
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

2.  Neu receptor dimerization.

Authors:  M J Sternberg; W J Gullick
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

3.  The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.

Authors:  T Akiyama; S Matsuda; Y Namba; T Saito; K Toyoshima; T Yamamoto
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

4.  Protein kinase C alpha activates RAF-1 by direct phosphorylation.

Authors:  W Kolch; G Heidecker; G Kochs; R Hummel; H Vahidi; H Mischak; G Finkenzeller; D Marmé; U R Rapp
Journal:  Nature       Date:  1993-07-15       Impact factor: 49.962

5.  Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation.

Authors:  E Peles; R Lamprecht; R Ben-Levy; E Tzahar; Y Yarden
Journal:  J Biol Chem       Date:  1992-06-15       Impact factor: 5.157

6.  Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.

Authors:  M E Furth; L J Davis; B Fleurdelys; E M Scolnick
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

Review 7.  Neu and its ligands: from an oncogene to neural factors.

Authors:  E Peles; Y Yarden
Journal:  Bioessays       Date:  1993-12       Impact factor: 4.345

8.  Raf-1 protein kinase is required for growth of induced NIH/3T3 cells.

Authors:  W Kolch; G Heidecker; P Lloyd; U R Rapp
Journal:  Nature       Date:  1991-01-31       Impact factor: 49.962

9.  Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.

Authors:  E Peles; R B Levy; E Or; A Ullrich; Y Yarden
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

10.  Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein.

Authors:  S J Leevers; C J Marshall
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more
  53 in total

1.  The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.

Authors:  H Waterman; I Alroy; S Strano; R Seger; Y Yarden
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.

Authors:  A Esparís-Ogando; E Díaz-Rodríguez; A Pandiella
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

3.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

Authors:  D L Dankort; Z Wang; V Blackmore; M F Moran; W J Muller
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Authors:  L N Klapper; S Glathe; N Vaisman; N E Hynes; G C Andrews; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium.

Authors:  T Improta-Brears; A R Whorton; F Codazzi; J D York; T Meyer; D P McDonnell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 6.  Oncogenic regulation and function of keratins 8 and 18.

Authors:  R G Oshima; H Baribault; C Caulín
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

7.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

Authors:  R Pinkas-Kramarski; L Soussan; H Waterman; G Levkowitz; I Alroy; L Klapper; S Lavi; R Seger; B J Ratzkin; M Sela; Y Yarden
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

8.  Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.

Authors:  A E Lenferink; R Pinkas-Kramarski; M L van de Poll; M J van Vugt; L N Klapper; E Tzahar; H Waterman; M Sela; E J van Zoelen; Y Yarden
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

9.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Subhankar Chakraborty; Subhash C Chauhan; Sangeeta Bafna; Jane L Meza; Pankaj K Singh; Michael A Hollingsworth; Parmender P Mehta; Surinder K Batra
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

10.  LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.

Authors:  M E Montañez-Wiscovich; D D Seachrist; M D Landis; J Visvader; B Andersen; R A Keri
Journal:  Oncogene       Date:  2009-08-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.